See more : EUWAX Aktiengesellschaft (EUX.F) Income Statement Analysis – Financial Results
Complete financial analysis of Gossamer Bio, Inc. (GOSS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gossamer Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Almarai Company (2280.SR) Income Statement Analysis – Financial Results
- Hitron Systems Inc. (019490.KS) Income Statement Analysis – Financial Results
- Pandora A/S (PANDY) Income Statement Analysis – Financial Results
- Onto Innovation Inc. (ONTO) Income Statement Analysis – Financial Results
- Mazaya Real Estate Development Q.P.S.C. (MRDS.QA) Income Statement Analysis – Financial Results
Gossamer Bio, Inc. (GOSS)
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.39M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 0.00 | 0.00 |
| Gross Profit | -4.39M | -4.43M | -5.17M | -4.27M | -3.09M | -297.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 145.30M | 170.92M | 170.27M | 160.85M | 143.40M | 55.28M | 891.00K | 0.00 |
| General & Administrative | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 38.46M | 47.61M | 45.78M | 49.73M | 39.14M | 44.05M | 262.00K | 83.00K |
| Other Expenses | 0.00 | 1.51M | 799.00K | -174.00K | 5.83M | 316.00K | 0.00 | 0.00 |
| Operating Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Cost & Expenses | 183.76M | 218.53M | 216.05M | 210.58M | 182.54M | 99.33M | 1.15M | 83.00K |
| Interest Income | 2.00M | 1.58M | 761.00K | 3.44M | 3.63K | 1.72M | 0.00 | 0.00 |
| Interest Expense | 13.51M | 13.88M | 19.44M | 12.67M | 0.00 | 12.00K | 118.00K | 0.00 |
| Depreciation & Amortization | 1.61M | 4.43M | 5.17M | 4.27M | 3.09M | 297.00K | 1.15M | 83.00K |
| EBITDA | -172.15M | -211.07M | -209.32M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -183.76M | -218.59M | -216.12M | -233.96M | -186.14M | -148.99M | -6.65M | -83.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.94M | -10.79M | -17.88M | -9.40M | 5.83M | 2.02M | -118.00K | 0.00 |
| Income Before Tax | -179.82M | -229.38M | -234.00M | -243.36M | -180.31M | -146.97M | -6.77M | -83.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 10.85M | 15.07M | 8.22M | 511.00K | 2.04M | -5.38M | -83.00K |
| Net Income | -179.82M | -240.23M | -249.08M | -251.58M | -180.82M | -146.97M | -6.77M | -83.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| EPS Diluted | -1.18 | -2.84 | -3.33 | -3.67 | -3.30 | -2.43 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
| Weighted Avg Shares Out (Dil) | 152.62M | 84.57M | 74.84M | 68.51M | 54.74M | 60.40M | 24.83M | 24.83M |
What Makes Gossamer Bio (GOSS) a New Buy Stock
This little-known biopharma stock could rally 70%: Goldman Sachs
Here's Why Gossamer Bio (GOSS) is a Great Momentum Stock to Buy
How to Find Penny Stocks to Buy in Summer 2022
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
Gossamer Bio Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Business Update
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
Gossamer Bio, Inc. (GOSS) CEO Faheem Hasnain on Q3 2021 Results - Earnings Call Transcript
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
Source: https://incomestatements.info
Category: Stock Reports